Stop missing ILD: AI reveals what the eye can't see

Written by The Life Science Feed Editorial Team · Published 6 September 2026 · Edited by Mara Voss

Interstitial lung disease (ILD) represents a complex and often progressive group of respiratory conditions, frequently presenting with non-specific symptoms that delay diagnosis. The insidious onset of ILD means patients often experience significant lung damage before a definitive diagnosis is made, limiting the effectiveness of available interventions. Earlier recognition is paramount for preserving lung function and improving long-term prognosis.

Combining advanced computational methods, specifically artificial intelligence (AI), with the insights of clinical specialists offers a promising avenue to overcome these diagnostic hurdles because it aims to identify subtle patterns in patient data that might otherwise be missed, leading to more timely and accurate diagnoses.

KEY TAKEAWAYS

- The Pivot: AI algorithms can augment clinical assessment to detect early signs of ILD, particularly in high-risk populations.
- The Data: AI models demonstrate the capacity to identify ILD features from imaging and clinical data with high sensitivity.
- The Action: Clinicians should consider integrating AI-assisted tools into their diagnostic pathways for patients with unexplained respiratory symptoms or risk factors for ILD.

Interstitial lung diseases encompass a diverse array of more than 200 distinct disorders, all characterised by progressive fibrosis and inflammation of the lung parenchyma. These conditions share common clinical features, including dyspnoea, cough, and fatigue, which are often mistakenly attributed to more common respiratory ailments like asthma or chronic obstructive pulmonary disease (COPD). The diagnostic journey for many ILD patients is protracted, often spanning several years from symptom onset to confirmed diagnosis. This delay is critical, as irreversible fibrotic changes can accumulate, diminishing the potential impact of antifibrotic therapies or immunomodulators.

The unmet need for earlier and more accurate diagnosis is substantial. Patients with conditions such as idiopathic pulmonary fibrosis (IPF), a particularly aggressive form of ILD, face a grim prognosis, often worse than many cancers, if not identified and treated promptly. Early intervention can slow disease progression, preserve lung function, and enhance quality of life. The challenge lies in distinguishing ILD from other respiratory conditions and, importantly, in identifying specific ILD subtypes that dictate different management strategies. This is where the synergy of clinical acumen and technological innovation becomes vital.

The Diagnostic Conundrum and AI's Role

Diagnosing ILD traditionally relies on a combination of clinical history, physical examination, pulmonary function tests (PFTs), and high-resolution computed tomography (HRCT) of the chest. A multidisciplinary team (MDT) discussion,

involving pulmonologists, radiologists, and pathologists, is often considered the gold standard for definitive diagnosis and subtyping. But this process is resource-intensive and not universally accessible, particularly in primary care settings or regions with limited specialist availability. General practitioners are often the first point of contact for patients presenting with respiratory symptoms, and they play a critical role in identifying individuals who warrant further investigation.

Artificial intelligence, particularly machine learning and deep learning algorithms, offers a powerful tool to enhance this diagnostic pathway. AI models can be trained on vast datasets of clinical information, including demographic data, symptom profiles, PFT results, and, most significantly, HRCT images. These algorithms learn to recognise subtle patterns and features that are indicative of ILD, even those imperceptible to the human eye or easily overlooked in a busy clinical environment. The goal is not to replace the clinician but to provide an intelligent assistant that flags suspicious cases, prioritises referrals, and offers decision support.

Leveraging Imaging and Clinical Data

HRCT imaging is central to ILD diagnosis, revealing characteristic patterns such as usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), and organising pneumonia. These patterns are essential for differentiating ILD subtypes. But interpreting HRCT scans requires specialised expertise, and inter-reader variability can occur. AI algorithms, particularly deep learning models like convolutional neural networks (CNNs), excel at image analysis. They can process hundreds of thousands of HRCT slices, learning to identify fibrotic reticulation, honeycombing, ground-glass opacities, and traction bronchiectasis with remarkable precision. This capability allows for automated detection of ILD features, potentially reducing the burden on radiologists and ensuring consistent interpretation.

Beyond imaging, AI can integrate diverse clinical data points. A patient's age, sex, smoking history, occupational exposures, and presence of autoimmune conditions are all relevant. For instance, a patient with rheumatoid arthritis presenting with new-onset dyspnoea and crackles on auscultation should raise suspicion for rheumatoid arthritis-associated ILD. AI models can weigh these factors, combining them with PFT results (e.g., reduced forced vital capacity or diffusing capacity for carbon monoxide) to generate a risk score or a probability of ILD. This holistic approach helps identify patients who might benefit from early referral to a pulmonologist, streamlining the diagnostic process and reducing delays. The diagnosis and management of ILD is a complex area, and AI can help guide clinicians through it.

The Promise of Early Detection

The primary benefit of earlier ILD recognition is the opportunity for timely therapeutic intervention. Antifibrotic drugs, such as pirfenidone and nintedanib, have demonstrated efficacy in slowing the decline of lung function in patients with IPF and other progressive fibrosing ILDs. But these agents are most effective when initiated before extensive, irreversible fibrosis has occurred. Delayed diagnosis means patients often start treatment at an advanced stage, where the potential for preserving lung function is diminished. AI-driven early detection could shift this paradigm, allowing for earlier initiation of these disease-modifying therapies.

Early diagnosis also facilitates better patient education and access to supportive care. Patients can be counselled on lifestyle modifications, pulmonary rehabilitation, and the importance of vaccination. They can also be monitored more closely for acute exacerbations, which are associated with significant morbidity and mortality. For some patients, early

identification might even open doors to clinical trials for novel therapies, offering options that would not be available if their disease was too advanced. This is particularly relevant for conditions like sarcoidosis, where early intervention can prevent progression to chronic fibrosis.

Integrating AI into Clinical Practice

Implementing AI tools into routine clinical practice requires careful consideration. The technology must be user-friendly, seamlessly integrated into existing electronic health record (EHR) systems, and provide actionable insights. For general practitioners, an AI-powered alert system could flag patients in their practice who exhibit a combination of symptoms, risk factors, and PFT abnormalities suggestive of ILD. This would prompt further investigation, such as an HRCT scan or referral to a specialist. For pulmonologists, AI could assist in the interpretation of complex HRCT patterns, highlighting areas of concern and suggesting potential diagnoses for MDT review. This integration could also extend to monitoring disease progression, with AI tracking changes in imaging over time to assess treatment response or identify worsening disease.

But, as with any emerging technology, there are caveats. The performance of AI models is highly dependent on the quality and diversity of the training data. Biases in the training data, such as an overrepresentation of certain ethnic groups or disease subtypes, could lead to disparities in diagnostic accuracy. Validation in real-world, diverse patient populations is essential to ensure generalisability and equitable application. The 'black box' nature of some deep learning models, where the exact reasoning behind a prediction is not transparent, can be a barrier to clinical adoption. Clinicians need to understand why an AI system is making a particular recommendation to trust and act upon it. The Oxford Handbook of Respiratory Medicine provides a comprehensive reference for understanding these diseases.

The Human Element Remains Central

Despite the advancements in AI, clinical expertise remains indispensable. AI is a tool to augment, not replace, the clinician's judgment. A positive AI signal for ILD still requires confirmation by a human expert, often within an MDT setting. The human clinician brings empathy, an understanding of the patient's individual circumstances, and the ability to interpret ambiguous findings in context. They can also account for factors not easily quantifiable by AI, such as subtle changes in a patient's voice or gait, or the impact of psychosocial factors on symptom perception. The interaction between patient and physician is a cornerstone of medical practice, and AI should serve to enhance this relationship by providing better information, not diminish it.

The development of explainable AI (XAI) is important for increasing clinician trust and adoption. XAI aims to make AI models more transparent, allowing clinicians to understand the features and patterns that led to a particular prediction. This transparency fosters collaboration between human and machine, enabling clinicians to critically evaluate AI recommendations and integrate them into their decision-making process with confidence. The future of ILD diagnosis will likely involve a symbiotic relationship, where AI handles the heavy lifting of data analysis and pattern recognition, while clinicians provide the critical oversight, contextual understanding, and compassionate care that define medical practice.

> **CLINICAL IMPLICATIONS**

> The potential for AI to accelerate ILD diagnosis is significant, offering a pathway to earlier intervention for a group of diseases where time is truly lung function. General practitioners, often the first point of contact, stand to benefit immensely from AI-powered screening tools that can flag at-risk patients, reducing the diagnostic odyssey that many currently endure.
>
> But, the integration of these technologies must be thoughtful. We cannot simply throw algorithms at the problem without considering the quality of the training data or the need for explainability. A 'black box' diagnosis, however accurate, will struggle to gain traction with clinicians who need to understand the rationale behind a recommendation.
>
> For patients, earlier diagnosis means a greater chance of benefiting from existing antifibrotic therapies and improved quality of life. It also means less time spent in diagnostic limbo, a period of anxiety and uncertainty that can be as debilitating as the disease itself. The industry must focus on developing AI solutions that are not only effective but also ethically sound and transparent.
>
> The goal is to empower clinicians with better tools, not to replace their expertise. The judgment of a pulmonologist, combined with the pattern-recognition capabilities of AI, represents the most potent weapon against the progression of interstitial lung disease. This collaborative approach will redefine the diagnostic standard, ensuring that more patients receive the right treatment at the right time.

REFERENCES

1. 1. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769-786. doi:10.1016/S0140-6736(22)01052-2
2. 2. Brixey AG, Oh AS, Alsamarraie A, Chung JH. Pictorial Review of Fibrotic Interstitial Lung Disease on High-Resolution CT Scan and Updated Classification. Chest. 2024;165(4):908-923. doi:10.1016/j.chest.2023.11.037
3. 3. Casal A, Suárez-Antelo J, Riveiro V, et al. Smoking-related interstitial lung disease: A narrative review. Chron Respir Dis. 2024;21:14799731241291538. doi:10.1177/14799731241291538
4. 4. Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol. 2020;38 Suppl 126(4):291-300. PMID:33095142
5. 5. Kadura S, Raghu G. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. Eur Respir Rev. 2021;30(162). doi:10.1183/16000617.0123-2021
6. 6. Kamiya M, Carter H, Espindola MS, et al. Immune mechanisms in fibrotic interstitial lung disease. Cell. 2024;187(14):3506-3530. doi:10.1016/j.cell.2024.05.015